MJ News for PURA
DALLAS, October 2, 2017 /PRNewswire/ -- North American Cannabis Holdings, Inc. (USOTC: USMJ) and Puration, Inc. (USOTC: PURA) today announced plans to present a shareholder update on October, 17, 2017 releasing details on the two companies' strategic shift in business concentration designed to enhance shareholder value. American Cannabis Innovations Conglomerated (ACI) recently acquired the controlling shareholder interest in Puration and North American Cannabis Holdings with plans to acquire shareholder interests in additional cannabis industry entrepreneurial companies. ACI recently launched a new consolidated website for USMJ and PURA (https://www.aciconglomerated.com) . The two companies anticipate publishing a number of press releases between now and the 17th making announcements pertinent to the upcoming strategic shift presentation. "Legal recreational marijuana will go into effect after the first of the year in California and this will be an earth shifting change in the landscape of the legal cannabis market nationwide," said Steven Rash, CEO of North American Cannabis Holdings and American Cannabis Innovations Conglomerated. "The magnitude of a legal cannabis market in a state the size of California in terms of tax revenue and overall economic contribution will accelerate momentum for legalization nationwide. I doubt moral outrage, let alone any deleterious crime impact, will hold a candle to the economic benefits of legal cannabis. In short, I expect legal recreational marijuana in California to make the case for legalization nationwide, and we expect to have North American Cannabis Holdings and Puration more ready then ever when the inevitable legalization of cannabis nationwide finally occurs." Learn more about ACI, USMJ and PURA by visiting: https://www.aciconglomerated.com Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. ACI, USMJ and PURA contact info: Steven Rash info@aciconglomerated.com +1-800-861-1350